Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

SCHRÖDINGER, INC.

(SDGR)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Schrödinger : University of Texas' MD Anderson, Schrodinger to Jointly Develop Anti-Cancer Treatments

10/07/2021 | 08:35am EST


© MT Newswires 2021
All news about SCHRÖDINGER, INC.
11/22Schrödinger to Participate in Five Upcoming Investor Conferences
BU
11/19Morgan Stanley Lowers Schrodinger to Equal-Weight From Overweight, Price Target to $49 ..
MT
11/18Piper Sandler Initiates Schrodinger With Overweight Rating, $87 Price Target
MT
11/18Schrödinger Awarded Grant to Accelerate Drug Discovery in Women's Health
BU
11/18Bill & Melinda Gates Foundation Awards Grants to Schr?dinger, Inc. to Accelerate Drug D..
CI
11/17Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BU
11/11Health Care Stocks Inch Higher in Premarket Thursday
MT
11/11Berenberg Bank Adjusts Schrodinger's Price Target to $89 From $91, Maintains Buy Rating
MT
11/11BofA Securities Cuts Schrodinger to Neutral From Buy, Price Target to $52 From $80
MT
11/10Schrodinger Posts Wider-Than-Expected Q3 Loss as Revenue Misses Street Consensus; Share..
MT
More news
Analyst Recommendations on SCHRÖDINGER, INC.
More recommendations
Financials (USD)
Sales 2021 129 M - -
Net income 2021 -93,8 M - -
Net cash 2021 336 M - -
P/E ratio 2021 -29,8x
Yield 2021 -
Capitalization 2 803 M 2 803 M -
EV / Sales 2021 19,2x
EV / Sales 2022 12,8x
Nbr of Employees 449
Free-Float 62,1%
Chart SCHRÖDINGER, INC.
Duration : Period :
Schrödinger, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SCHRÖDINGER, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Last Close Price 39,54 $
Average target price 74,00 $
Spread / Average Target 87,2%
EPS Revisions
Managers and Directors
Ramy Farid President, Chief Executive Officer & Director
Joel Lebowitz Chief Financial Officer & Executive Vice President
Michael M. Lynton Chairman
Shane Brauner Chief Information Officer & Executive VP
Patrick Lorton Chief Technology Officer & Executive VP
Sector and Competitors
1st jan.Capi. (M$)
SCHRÖDINGER, INC.-50.06%2 803
MICROSOFT CORPORATION48.22%2 475 231
SEA LIMITED49.12%164 624
ATLASSIAN CORPORATION PLC67.42%98 962
DASSAULT SYSTÈMES SE59.16%78 695
ROBLOX CORPORATION0.00%70 994